Search
Jul 25
AI x Bio Summit: Generate Biomedicines' CEO Mike Nally gives an update on the company's clinical and emerging programs
He describes clinical programs targeting COVID and TSLP, as well as emerging programs in the ADC space, TL1A, IL13, and more.
Sep 18, 2023
Generate Biomedicines' Mike Nally on Thursday's $273M Series C and computational drug development
Mike Nally describes Generate's near term programs how he sees computational advances changing where the field is headed over the long term.
Jan 11, 2023
AI in biotech with Generate Biomedicines’ Mike Nally
Generate Biomedicine's Mike Nally describes how AI might impact biotech in the future at #JPM23.
.png){kind=logo}
